SCHEMBL6483232

SCHEMBL6483232

COc1ccccc1CNc1ccc2c(c1)Cc1ccccc1-2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
MAPK1 P28482 3/20 0.56
KDM4E B2RXH2 3/20 0.56
RAB9A P51151 2/20 0.56
ALDH1A1 P00352 4/20 0.53
TSHR P16473 3/20 0.53
MAPT P10636 3/20 0.53
GAA P10253 1/20 0.53
ALOX15 P16050 1/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP1A2 P05177 4/20 0.52
LMNA P02545 3/20 0.52
HIF1A Q16665 3/20 0.52
CYP3A4 P08684 3/20 0.52
TP53 P04637 2/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C19 P33261 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482117 0.82 DHFR (0.54) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6495966 0.80 CYP1A2 (0.49) MEN1KMT2ARAB9AMAPTGAA
SCHEMBL6490390 0.80 CYP1A2 (0.49) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6483935 0.80 CYP1A2 (0.55) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6494134 0.80 MAPT (0.55) MEN1KMT2AKDM4ERAB9AMAPT
SCHEMBL6482846 0.79 MAPT (0.52) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6483979 0.79 MAPT (0.53) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6490115 0.79 DHFR (0.46) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6481576 0.79 MAPT (0.59) MEN1KMT2AMAPK1KDM4ERAB9A
SCHEMBL6482900 0.78 DHFR (0.53) MEN1KMT2AMAPK1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MEN1 3995/4885KMT2A 412/4885MAPK1 3800/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MEN1 3464/4885KMT2A 770/4885MAPK1 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.